What is DNTH's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 4.61B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for DNTH?

P/E (TTM) is n/a and 52-week range is $32.22 to $117.88 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s DNTH figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for DNTH?

The company profile lists revenue (TTM) near $2M, net income (TTM) near $-18.77B, EPS (TTM) near $-4.15 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Dianthus Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in New York City, New York, US, 54.7M shares outstanding, ISIN US2528281080 when available from company profile and filing metadata.

Dianthus Therapeutics Inc

$DNTH

Health Care · Biotechnology

IR Run Scenarios

$82.37

-0.07%

Dianthus Therapeutics Inc

$DNTH

Health Care · Biotechnology

IR Run Scenarios

$82.37

-0.07%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in New York City, New York and currently employs 92 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. The company is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).

Employees

92

Website

dianthustx.com/

IPO

2018-06-21

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (TTM)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US2528281080

Headquarters

New York City, New York, US

Shares outstanding

54.7M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

127.71%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. The company is headquartered in New York City, New York and currently employs 92 full-time employees. The company went IPO on 2018-06-21. The firm is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. The company is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).

Employees

92

Website

dianthustx.com/

IPO

2018-06-21

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)